Atherosclerosis Drugs Market By Drug Type (Anti-platelet and Anticoagulants, Cholesterol Lowering Medication, ACE Inhibitors, Others), By Route of Administration (Oral, Injectable), By Distribution Channel (Hospital Pharmacies, Online Providers, Drug Stores and Retail Pharmacies): Global Opportunity Analysis and Industry Forecast, 2023-2032

Atherosclerosis Drugs Market

Atherosclerosis is a disorder in which veins get narrowed due to build of plaque in veins. Plaque that forms in blood artery obstruct the flow of blood, which results in increase in blood pressure. This causes the formation of blood clots in blood stream, which may increase the risk of heart attack, coronary artery diseases, or peripheral artery diseases. 

Key factors driving the growth of the atherosclerosis drugs market include rise in p rise in cases of obesity, especially in urban areas, rise in initiatives taken by governments and corporates to promote healthy lifestyle. Obesity is associated with several health issues, such as sudden cardiac arrest, hypertension, hypotension, and diabetes. For instance, the World Obesity Atlas 2022 estimated that one billion people globally, including 1 in 5 women and 1 in 7 men, are expected to be living with obesity by 2030. Thus, there is an increase in cases of obesity which, in turn, increases the risk of cardiovascular diseases that drives the demand for atherosclerosis drugs and further propels the market growth. 

In addition, major key players in atherosclerosis drugs market are focusing on intensifying research activities to develop atherosclerosis medications support the market growth. Moreover, rise in prevalence of cardiovascular conditions due to plaque formation is leading to increase in demand for new treatment options. For instance, the Sheba Medical Center created a novel polymer called E-selectin-targeting polymer. By lowering or reducing the buildup of plaque in the arteries, this innovative treatment for atherosclerosis lowers the risk of ischemia, stroke, arterial thrombosis, and myocardial infarction. 

Furthermore, high cholesterol level due to decrease in physical activities and sedentary lifestyle and surge in number of product approvals for atherosclerosis treatment is expected to drive the growth of the market. For instance, slightly more than half of the U.S. adults (54.5%, or 47 million people) who could benefit from cholesterol lowering medicine are currently taking it. 

The market also offers growth opportunities to the key players in the market. Rise in number of pharmaceutical industries and increase in demand for atherosclerosis drugs which are anticipated to provide lucrative opportunities for the expansion of the market during the forecast period. In addition, several manufacturers focus on developing drugs for the treatment of atherosclerosis are in pipeline at various stages of development which further support the market growth. Furthermore, rise in healthcare spending significantly impacts the growth of the pharmaceutical sector. This results in increased production of atherosclerosis treatment products, thereby driving the growth of the market.   

The atherosclerosis drugs market is segmented into drug type, route of administration, distribution channel, and region. On the basis of drug type, the market is categorized into antiplatelets & anticoagulants, cholesterol lowering medication, ACE inhibitors, and others. On the basis of route of administration, it is bifurcated into oral, and injectable. On the basis of distribution channel, it is divided into hospital pharmacies, online providers, and drug stores and retail pharmacies. Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and rest of Europe), Asia-Pacific (China, India, Japan, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA). 

The key players profiled in the study include Amgen Inc., Pfizer Inc., AstraZeneca, Bayer AG, Sanofi, Novartis AG, Viatris, Johnson & Johnson, Lupin, and Bausch Health Companies Inc. The players in the market have been actively engaged in the adoption of strategies such as product approval to remain competitive and gain advantage over the competitors in the market. For instance, in Sepetember 2021, mgen announced that U.S. Food and Drug Administration (FDA) has approved Repatha (evolocumab) as an adjunct to diet and other low-density lipoprotein cholesterol (LDL-C)-lowering therapies for the treatment of pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH) to reduce LDL-C. 

Key Market Insights 

By drug type, the antiplatelet and anticoagulant segment was the largest revenue contributor to the market and is estimated to reach $15093.06 million. However, the cholesterol lowering medication segment is expected to be the fastest-growing segment with a CAGR of 4.2% during the forecast period.     

By route of administration, the oral segment dominated the global market. However, the injectable segment is expected to be the fastest-growing segment with a CAGR of 4.5% during the forecast period. 

Based on distribution channel, the drug stores & retail pharmacies segment was the largest revenue contributor to the market in 2022. However, the online providers segment is expected to be the fastest-growing segment with a CAGR of 4.1% during the forecast period.   

Based on region, North America garnered the largest revenue share in 2022, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period. 

Overview

The atherosclerosis drugs market valued for $20,608.51 million in 2022 and is estimated to reach $27,711.92 million by 2032, exhibiting a CAGR of 3% from 2023 to 2032.   

Atherosclerosis is a disorder in which veins get narrowed due to build of plaque, thus stiffening the artery walls. Blood flow is obstructed by plaque that builds up in blood vessels, which raises blood pressure. Formation of blood clots in the bloodstream is common in this condition, which can further lead to heart attack, coronary artery diseases, or peripheral artery diseases.    

Atherosclerosis drugs aim to reduce the formation of plaque or its effects on the body by reducing cholesterol levels, decreasing inflammation, preventing blood clots, and improving blood flow. Commonly used atherosclerosis drugs include antiplatelet drugs such as aspirin, which prevent blood clots; angiotensin-converting enzyme (ACE) inhibitors, which reduce blood pressure; and beta-blockers, which minimize the risk of heart attack along with maintaining the blood pressure.   

The growth of the global atherosclerosis drugs market is majorly driven by alarming increase in cardiovascular disorders. In addition, rise in awareness of early diagnosis and treatment of atherosclerosis boosts the demand for atherosclerosis drugs, which positively impacts the growth of the market.  However, surge in cost associated with R&D of atherosclerosis drugs is expected to impede the market growth. In contrast, surge in investments for novel drug therapeutics in public as well as private sectors is anticipated to provide lucrative opportunities for the growth of the atherosclerosis drugs market during the forecast period.     

Furthermore, rise in healthcare expenditure in both developed and developing countries drives demand for atherosclerosis drugs, as healthcare providers seek to offer the latest and most effective treatments to their patients.    

The global atherosclerosis drugs market is segmented into drug type, route of administration, distribution channel, and region. On the basis of drug type, the market is categorized into anti-platelet & anticoagulants, cholesterol lowering medication, ACE inhibitors, and others. Depending on route of administration, it is bifurcated into oral and injectable. By distribution channel, it is classified into hospital pharmacies, online providers, and drug stores & retail pharmacies.   

Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).   

The report provides a comprehensive analysis of the key players that operate in the global atherosclerosis drugs market. The key companies profiled in the report include Amgen Inc., Pfizer Inc., AstraZeneca, Bayer AG, Sanofi, Novartis AG, Viatris, Johnson & Johnson, Lupin, and Bausch Health Companies Inc. 

Key Benefits For Stakeholders

●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the atherosclerosis drugs market analysis from 2022 to 2032 to identify the prevailing atherosclerosis drugs market opportunities.

●The market research is offered along with information related to key drivers, restraints, and opportunities.

●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

●In-depth analysis of the atherosclerosis drugs market segmentation assists to determine the prevailing market opportunities.

●Major countries in each region are mapped according to their revenue contribution to the global market.

●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

●The report includes the analysis of the regional as well as global atherosclerosis drugs market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

○ Viatris Inc

Scope of Atherosclerosis Drugs Market Report

1.1. Report description

1.2. Key market segments

1.3. Key benefits to the stakeholders

1.4. Research Methodology

1.4.1. Primary research

1.4.2. Secondary research

1.4.3. Analyst tools and models

2.1. CXO Perspective

3.1. Market definition and scope

3.2. Key findings

3.2.1. Top impacting factors

3.2.2. Top investment pockets

3.3. Porter’s five forces analysis

3.3.1. Bargaining power of suppliers

3.3.2. Bargaining power of buyers

3.3.3. Threat of substitutes

3.3.4. Threat of new entrants

3.3.5. Intensity of rivalry

3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Surge in obesity in populace

3.4.1.2. Increase in government initiatives to promote healthy lifestyle

3.4.1.3. Development of new treatments for atherosclerosis

3.4.2. Restraints

3.4.2.1. Side effects of atherosclerosis drugs

3.4.3. Opportunities

3.4.3.1. Growth opportunities in the emerging markets

3.5. COVID-19 Impact Analysis on the market

4.1. Overview

4.1.1. Market size and forecast

4.2. Anti-platelet and Anticoagulants

4.2.1. Key market trends, growth factors and opportunities

4.2.2. Market size and forecast, by region

4.2.3. Market share analysis by country

4.3. Cholesterol Lowering Medication

4.3.1. Key market trends, growth factors and opportunities

4.3.2. Market size and forecast, by region

4.3.3. Market share analysis by country

4.4. ACE Inhibitors

4.4.1. Key market trends, growth factors and opportunities

4.4.2. Market size and forecast, by region

4.4.3. Market share analysis by country

4.5. Others

4.5.1. Key market trends, growth factors and opportunities

4.5.2. Market size and forecast, by region

4.5.3. Market share analysis by country

5.1. Overview

5.1.1. Market size and forecast

5.2. Oral

5.2.1. Key market trends, growth factors and opportunities

5.2.2. Market size and forecast, by region

5.2.3. Market share analysis by country

5.3. Injectable

5.3.1. Key market trends, growth factors and opportunities

5.3.2. Market size and forecast, by region

5.3.3. Market share analysis by country

6.1. Overview

6.1.1. Market size and forecast

6.2. Hospital Pharmacies

6.2.1. Key market trends, growth factors and opportunities

6.2.2. Market size and forecast, by region

6.2.3. Market share analysis by country

6.3. Online Providers

6.3.1. Key market trends, growth factors and opportunities

6.3.2. Market size and forecast, by region

6.3.3. Market share analysis by country

6.4. Drug Stores and Retail Pharmacies

6.4.1. Key market trends, growth factors and opportunities

6.4.2. Market size and forecast, by region

6.4.3. Market share analysis by country

7.1. Overview

7.1.1. Market size and forecast By Region

7.2. North America

7.2.1. Key trends and opportunities

7.2.2. Market size and forecast, by Drug Type

7.2.3. Market size and forecast, by Route of Administration

7.2.4. Market size and forecast, by Distribution Channel

7.2.5. Market size and forecast, by country

7.2.5.1. U.S.

7.2.5.1.1. Key market trends, growth factors and opportunities

7.2.5.1.2. Market size and forecast, by Drug Type

7.2.5.1.3. Market size and forecast, by Route of Administration

7.2.5.1.4. Market size and forecast, by Distribution Channel

7.2.5.2. Canada

7.2.5.2.1. Key market trends, growth factors and opportunities

7.2.5.2.2. Market size and forecast, by Drug Type

7.2.5.2.3. Market size and forecast, by Route of Administration

7.2.5.2.4. Market size and forecast, by Distribution Channel

7.2.5.3. Mexico

7.2.5.3.1. Key market trends, growth factors and opportunities

7.2.5.3.2. Market size and forecast, by Drug Type

7.2.5.3.3. Market size and forecast, by Route of Administration

7.2.5.3.4. Market size and forecast, by Distribution Channel

7.3. Europe

7.3.1. Key trends and opportunities

7.3.2. Market size and forecast, by Drug Type

7.3.3. Market size and forecast, by Route of Administration

7.3.4. Market size and forecast, by Distribution Channel

7.3.5. Market size and forecast, by country

7.3.5.1. Germany

7.3.5.1.1. Key market trends, growth factors and opportunities

7.3.5.1.2. Market size and forecast, by Drug Type

7.3.5.1.3. Market size and forecast, by Route of Administration

7.3.5.1.4. Market size and forecast, by Distribution Channel

7.3.5.2. France

7.3.5.2.1. Key market trends, growth factors and opportunities

7.3.5.2.2. Market size and forecast, by Drug Type

7.3.5.2.3. Market size and forecast, by Route of Administration

7.3.5.2.4. Market size and forecast, by Distribution Channel

7.3.5.3. UK

7.3.5.3.1. Key market trends, growth factors and opportunities

7.3.5.3.2. Market size and forecast, by Drug Type

7.3.5.3.3. Market size and forecast, by Route of Administration

7.3.5.3.4. Market size and forecast, by Distribution Channel

7.3.5.4. Italy

7.3.5.4.1. Key market trends, growth factors and opportunities

7.3.5.4.2. Market size and forecast, by Drug Type

7.3.5.4.3. Market size and forecast, by Route of Administration

7.3.5.4.4. Market size and forecast, by Distribution Channel

7.3.5.5. Spain

7.3.5.5.1. Key market trends, growth factors and opportunities

7.3.5.5.2. Market size and forecast, by Drug Type

7.3.5.5.3. Market size and forecast, by Route of Administration

7.3.5.5.4. Market size and forecast, by Distribution Channel

7.3.5.6. Rest of Europe

7.3.5.6.1. Key market trends, growth factors and opportunities

7.3.5.6.2. Market size and forecast, by Drug Type

7.3.5.6.3. Market size and forecast, by Route of Administration

7.3.5.6.4. Market size and forecast, by Distribution Channel

7.4. Asia-Pacific

7.4.1. Key trends and opportunities

7.4.2. Market size and forecast, by Drug Type

7.4.3. Market size and forecast, by Route of Administration

7.4.4. Market size and forecast, by Distribution Channel

7.4.5. Market size and forecast, by country

7.4.5.1. Japan

7.4.5.1.1. Key market trends, growth factors and opportunities

7.4.5.1.2. Market size and forecast, by Drug Type

7.4.5.1.3. Market size and forecast, by Route of Administration

7.4.5.1.4. Market size and forecast, by Distribution Channel

7.4.5.2. China

7.4.5.2.1. Key market trends, growth factors and opportunities

7.4.5.2.2. Market size and forecast, by Drug Type

7.4.5.2.3. Market size and forecast, by Route of Administration

7.4.5.2.4. Market size and forecast, by Distribution Channel

7.4.5.3. Australia

7.4.5.3.1. Key market trends, growth factors and opportunities

7.4.5.3.2. Market size and forecast, by Drug Type

7.4.5.3.3. Market size and forecast, by Route of Administration

7.4.5.3.4. Market size and forecast, by Distribution Channel

7.4.5.4. India

7.4.5.4.1. Key market trends, growth factors and opportunities

7.4.5.4.2. Market size and forecast, by Drug Type

7.4.5.4.3. Market size and forecast, by Route of Administration

7.4.5.4.4. Market size and forecast, by Distribution Channel

7.4.5.5. South Korea

7.4.5.5.1. Key market trends, growth factors and opportunities

7.4.5.5.2. Market size and forecast, by Drug Type

7.4.5.5.3. Market size and forecast, by Route of Administration

7.4.5.5.4. Market size and forecast, by Distribution Channel

7.4.5.6. Rest of Asia-Pacific

7.4.5.6.1. Key market trends, growth factors and opportunities

7.4.5.6.2. Market size and forecast, by Drug Type

7.4.5.6.3. Market size and forecast, by Route of Administration

7.4.5.6.4. Market size and forecast, by Distribution Channel

7.5. LAMEA

7.5.1. Key trends and opportunities

7.5.2. Market size and forecast, by Drug Type

7.5.3. Market size and forecast, by Route of Administration

7.5.4. Market size and forecast, by Distribution Channel

7.5.5. Market size and forecast, by country

7.5.5.1. Brazil

7.5.5.1.1. Key market trends, growth factors and opportunities

7.5.5.1.2. Market size and forecast, by Drug Type

7.5.5.1.3. Market size and forecast, by Route of Administration

7.5.5.1.4. Market size and forecast, by Distribution Channel

7.5.5.2. Saudi Arabia

7.5.5.2.1. Key market trends, growth factors and opportunities

7.5.5.2.2. Market size and forecast, by Drug Type

7.5.5.2.3. Market size and forecast, by Route of Administration

7.5.5.2.4. Market size and forecast, by Distribution Channel

7.5.5.3. South Africa

7.5.5.3.1. Key market trends, growth factors and opportunities

7.5.5.3.2. Market size and forecast, by Drug Type

7.5.5.3.3. Market size and forecast, by Route of Administration

7.5.5.3.4. Market size and forecast, by Distribution Channel

7.5.5.4. Rest of LAMEA

7.5.5.4.1. Key market trends, growth factors and opportunities

7.5.5.4.2. Market size and forecast, by Drug Type

7.5.5.4.3. Market size and forecast, by Route of Administration

7.5.5.4.4. Market size and forecast, by Distribution Channel

8.1. Introduction

8.2. Top winning strategies

8.3. Product Mapping of Top 10 Player

8.4. Competitive Dashboard

8.5. Competitive Heatmap

8.6. Top player positioning, 2022

9.1. Amgen Inc.

9.1.1. Company overview

9.1.2. Key Executives

9.1.3. Company snapshot

9.1.4. Operating business segments

9.1.5. Product portfolio

9.1.6. Business performance

9.1.7. Key strategic moves and developments

9.2. Pfizer Inc.

9.2.1. Company overview

9.2.2. Key Executives

9.2.3. Company snapshot

9.2.4. Operating business segments

9.2.5. Product portfolio

9.2.6. Business performance

9.3. AstraZeneca

9.3.1. Company overview

9.3.2. Key Executives

9.3.3. Company snapshot

9.3.4. Operating business segments

9.3.5. Product portfolio

9.3.6. Business performance

9.3.7. Key strategic moves and developments

9.4. Bayer AG

9.4.1. Company overview

9.4.2. Key Executives

9.4.3. Company snapshot

9.4.4. Operating business segments

9.4.5. Product portfolio

9.4.6. Business performance

9.4.7. Key strategic moves and developments

9.5. Sanofi

9.5.1. Company overview

9.5.2. Key Executives

9.5.3. Company snapshot

9.5.4. Operating business segments

9.5.5. Product portfolio

9.5.6. Business performance

9.5.7. Key strategic moves and developments

9.6. Novartis AG

9.6.1. Company overview

9.6.2. Key Executives

9.6.3. Company snapshot

9.6.4. Operating business segments

9.6.5. Product portfolio

9.6.6. Business performance

9.6.7. Key strategic moves and developments

9.7. Viatris Inc.

9.7.1. Company overview

9.7.2. Key Executives

9.7.3. Company snapshot

9.7.4. Operating business segments

9.7.5. Product portfolio

9.7.6. Business performance

9.8. Bausch Health Companies Inc.

9.8.1. Company overview

9.8.2. Key Executives

9.8.3. Company snapshot

9.8.4. Operating business segments

9.8.5. Product portfolio

9.8.6. Business performance

9.9. Lupin

9.9.1. Company overview

9.9.2. Key Executives

9.9.3. Company snapshot

9.9.4. Operating business segments

9.9.5. Product portfolio

9.9.6. Business performance

9.10. Johnson & Johnson

9.10.1. Company overview

9.10.2. Key Executives

9.10.3. Company snapshot

9.10.4. Operating business segments

9.10.5. Product portfolio

9.10.6. Business performanc

LIST OF TABLES

TABLE 01. GLOBAL ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 02. ATHEROSCLEROSIS DRUGS MARKET FOR ANTI-PLATELET AND ANTICOAGULANTS, BY REGION, 2022-2032 ($MILLION)

TABLE 03. ATHEROSCLEROSIS DRUGS MARKET FOR CHOLESTEROL LOWERING MEDICATION, BY REGION, 2022-2032 ($MILLION)

TABLE 04. ATHEROSCLEROSIS DRUGS MARKET FOR ACE INHIBITORS, BY REGION, 2022-2032 ($MILLION)

TABLE 05. ATHEROSCLEROSIS DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)

TABLE 06. GLOBAL ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 07. ATHEROSCLEROSIS DRUGS MARKET FOR ORAL, BY REGION, 2022-2032 ($MILLION)

TABLE 08. ATHEROSCLEROSIS DRUGS MARKET FOR INJECTABLE, BY REGION, 2022-2032 ($MILLION)

TABLE 09. GLOBAL ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 10. ATHEROSCLEROSIS DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)

TABLE 11. ATHEROSCLEROSIS DRUGS MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)

TABLE 12. ATHEROSCLEROSIS DRUGS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)

TABLE 13. ATHEROSCLEROSIS DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)

TABLE 14. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 15. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 16. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 17. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 18. U.S. ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 19. U.S. ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 20. U.S. ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 21. CANADA ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 22. CANADA ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 23. CANADA ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 24. MEXICO ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 25. MEXICO ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 26. MEXICO ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 27. EUROPE ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 28. EUROPE ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 29. EUROPE ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 30. EUROPE ATHEROSCLEROSIS DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 31. GERMANY ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 32. GERMANY ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 33. GERMANY ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 34. FRANCE ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 35. FRANCE ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 36. FRANCE ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 37. UK ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 38. UK ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 39. UK ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 40. ITALY ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 41. ITALY ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 42. ITALY ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 43. SPAIN ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 44. SPAIN ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 45. SPAIN ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 46. REST OF EUROPE ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 47. REST OF EUROPE ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 48. REST OF EUROPE ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 49. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 50. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 51. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 52. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 53. JAPAN ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 54. JAPAN ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 55. JAPAN ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 56. CHINA ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 57. CHINA ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 58. CHINA ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 59. AUSTRALIA ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 60. AUSTRALIA ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 61. AUSTRALIA ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 62. INDIA ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 63. INDIA ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 64. INDIA ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 65. SOUTH KOREA ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 66. SOUTH KOREA ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 67. SOUTH KOREA ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 68. REST OF ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 69. REST OF ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 70. REST OF ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 71. LAMEA ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 72. LAMEA ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 73. LAMEA ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 74. LAMEA ATHEROSCLEROSIS DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 75. BRAZIL ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 76. BRAZIL ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 77. BRAZIL ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 78. SAUDI ARABIA ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 79. SAUDI ARABIA ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 80. SAUDI ARABIA ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 81. SOUTH AFRICA ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 82. SOUTH AFRICA ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 83. SOUTH AFRICA ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 84. REST OF LAMEA ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 85. REST OF LAMEA ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 86. REST OF LAMEA ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 87. AMGEN INC.: KEY EXECUTIVES

TABLE 88. AMGEN INC.: COMPANY SNAPSHOT

TABLE 89. AMGEN INC.: PRODUCT SEGMENTS

TABLE 90. AMGEN INC.: PRODUCT PORTFOLIO

TABLE 91. AMGEN INC.: KEY STRATERGIES

TABLE 92. PFIZER INC.: KEY EXECUTIVES

TABLE 93. PFIZER INC.: COMPANY SNAPSHOT

TABLE 94. PFIZER INC.: PRODUCT SEGMENTS

TABLE 95. PFIZER INC.: PRODUCT PORTFOLIO

TABLE 96. ASTRAZENECA: KEY EXECUTIVES

TABLE 97. ASTRAZENECA: COMPANY SNAPSHOT

TABLE 98. ASTRAZENECA: PRODUCT SEGMENTS

TABLE 99. ASTRAZENECA: PRODUCT PORTFOLIO

TABLE 100. ASTRAZENECA: KEY STRATERGIES

TABLE 101. BAYER AG: KEY EXECUTIVES

TABLE 102. BAYER AG: COMPANY SNAPSHOT

TABLE 103. BAYER AG: PRODUCT SEGMENTS

TABLE 104. BAYER AG: PRODUCT PORTFOLIO

TABLE 105. BAYER AG: KEY STRATERGIES

TABLE 106. SANOFI: KEY EXECUTIVES

TABLE 107. SANOFI: COMPANY SNAPSHOT

TABLE 108. SANOFI: PRODUCT SEGMENTS

TABLE 109. SANOFI: PRODUCT PORTFOLIO

TABLE 110. SANOFI: KEY STRATERGIES

TABLE 111. NOVARTIS AG: KEY EXECUTIVES

TABLE 112. NOVARTIS AG: COMPANY SNAPSHOT

TABLE 113. NOVARTIS AG: PRODUCT SEGMENTS

TABLE 114. NOVARTIS AG: PRODUCT PORTFOLIO

TABLE 115. NOVARTIS AG: KEY STRATERGIES

TABLE 116. VIATRIS INC.: KEY EXECUTIVES

TABLE 117. VIATRIS INC.: COMPANY SNAPSHOT

TABLE 118. VIATRIS INC.: PRODUCT SEGMENTS

TABLE 119. VIATRIS INC.: PRODUCT PORTFOLIO

TABLE 120. BAUSCH HEALTH COMPANIES INC.: KEY EXECUTIVES

TABLE 121. BAUSCH HEALTH COMPANIES INC.: COMPANY SNAPSHOT

TABLE 122. BAUSCH HEALTH COMPANIES INC.: PRODUCT SEGMENTS

TABLE 123. BAUSCH HEALTH COMPANIES INC.: PRODUCT PORTFOLIO

TABLE 124. LUPIN: KEY EXECUTIVES

TABLE 125. LUPIN: COMPANY SNAPSHOT

TABLE 126. LUPIN: PRODUCT SEGMENTS

TABLE 127. LUPIN: PRODUCT PORTFOLIO

TABLE 128. JOHNSON & JOHNSON: KEY EXECUTIVES

TABLE 129. JOHNSON & JOHNSON: COMPANY SNAPSHOT

TABLE 130. JOHNSON & JOHNSON: PRODUCT SEGMENTS

TABLE 131. JOHNSON & JOHNSON: PRODUCT PORTFOLIO LIST OF FIGURES

FIGURE 01. ATHEROSCLEROSIS DRUGS MARKET, 2022-2032

FIGURE 02. SEGMENTATION OF ATHEROSCLEROSIS DRUGS MARKET, 2022-2032

FIGURE 03. TOP INVESTMENT POCKETS IN ATHEROSCLEROSIS DRUGS MARKET (2023-2032)

FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS

FIGURE 05. LOW BARGAINING POWER OF BUYERS

FIGURE 06. LOW THREAT OF SUBSTITUTES

FIGURE 07. LOW THREAT OF NEW ENTRANTS

FIGURE 08. LOW INTENSITY OF RIVALRY

FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALATHEROSCLEROSIS DRUGS MARKET

FIGURE 10. ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022(%)

FIGURE 11. COMPARATIVE SHARE ANALYSIS OF ATHEROSCLEROSIS DRUGS MARKET FOR ANTI-PLATELET AND ANTICOAGULANTS, BY COUNTRY 2022 AND 2032(%)

FIGURE 12. COMPARATIVE SHARE ANALYSIS OF ATHEROSCLEROSIS DRUGS MARKET FOR CHOLESTEROL LOWERING MEDICATION, BY COUNTRY 2022 AND 2032(%)

FIGURE 13. COMPARATIVE SHARE ANALYSIS OF ATHEROSCLEROSIS DRUGS MARKET FOR ACE INHIBITORS, BY COUNTRY 2022 AND 2032(%)

FIGURE 14. COMPARATIVE SHARE ANALYSIS OF ATHEROSCLEROSIS DRUGS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)

FIGURE 15. ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022(%)

FIGURE 16. COMPARATIVE SHARE ANALYSIS OF ATHEROSCLEROSIS DRUGS MARKET FOR ORAL, BY COUNTRY 2022 AND 2032(%)

FIGURE 17. COMPARATIVE SHARE ANALYSIS OF ATHEROSCLEROSIS DRUGS MARKET FOR INJECTABLE, BY COUNTRY 2022 AND 2032(%)

FIGURE 18. ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022(%)

FIGURE 19. COMPARATIVE SHARE ANALYSIS OF ATHEROSCLEROSIS DRUGS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)

FIGURE 20. COMPARATIVE SHARE ANALYSIS OF ATHEROSCLEROSIS DRUGS MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2022 AND 2032(%)

FIGURE 21. COMPARATIVE SHARE ANALYSIS OF ATHEROSCLEROSIS DRUGS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)

FIGURE 22. ATHEROSCLEROSIS DRUGS MARKET BY REGION, 2022

FIGURE 23. U.S. ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 24. CANADA ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 25. MEXICO ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 26. GERMANY ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 27. FRANCE ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 28. UK ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 29. ITALY ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 30. SPAIN ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 31. REST OF EUROPE ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 32. JAPAN ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 33. CHINA ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 34. AUSTRALIA ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 35. INDIA ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 36. SOUTH KOREA ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 37. REST OF ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 38. BRAZIL ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 39. SAUDI ARABIA ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 40. SOUTH AFRICA ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 41. REST OF LAMEA ATHEROSCLEROSIS DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 42. TOP WINNING STRATEGIES, BY YEAR

FIGURE 43. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 44. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 45. PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 46. COMPETITIVE DASHBOARD

FIGURE 47. COMPETITIVE HEATMAP: ATHEROSCLEROSIS DRUGS MARKET

FIGURE 48. TOP PLAYER POSITIONING, 2022

FIGURE 49. AMGEN INC.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 50. AMGEN INC.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 51. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 52. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 53. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 54. ASTRAZENECA: NET SALES, 2020-2022 ($MILLION)

FIGURE 55. ASTRAZENECA: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 56. BAYER AG: NET SALES, 2020-2022 ($MILLION)

FIGURE 57. BAYER AG: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 58. BAYER AG: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 59. SANOFI: NET SALES, 2020-2022 ($MILLION)

FIGURE 60. SANOFI: REVENUE SHARE BY SEGMENT, 2021 (%)

FIGURE 61. SANOFI: REVENUE SHARE BY REGION, 2021 (%)

FIGURE 62. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)

FIGURE 63. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 64. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 65. VIATRIS INC.: NET SALES, 2020-2022 ($MILLION)

FIGURE 66. VIATRIS INC.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 67. BAUSCH HEALTH COMPANIES INC.: NET REVENUE, 2019-2021 ($MILLION)

FIGURE 68. BAUSCH HEALTH COMPANIES INC.: REVENUE SHARE BY SEGMENT, 2021 (%)

FIGURE 69. BAUSCH HEALTH COMPANIES INC.: REVENUE SHARE BY REGION, 2021 (%)

FIGURE 70. LUPIN: NET SALES, 2019-2021 ($MILLION)

FIGURE 71. LUPIN: REVENUE SHARE BY REGION, 2021 (%)

FIGURE 72. JOHNSON & JOHNSON: NET SALES, 2020-2022 ($MILLION)

FIGURE 73. JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 74. JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2022 (%